NCT01784120 A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer Status UNKNOWN Phase PHASE2
NCT01773460 Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane Status TERMINATED Phase PHASE3
NCT01733628 Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer Status COMPLETED Phase N/A
NCT01730677 Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab Status UNKNOWN Phase PHASE2
NCT01715155 Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study Status COMPLETED Phase N/A
NCT01701050 Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Status COMPLETED Phase N/A
NCT01663727 Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer Status COMPLETED Phase PHASE3
NCT01660529 Multi-peptide Vaccine With Basilixumab for Breast Cancer Status COMPLETED Phase EARLY_PHASE1
NCT01658033 Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients Status COMPLETED Phase PHASE2
NCT01656538 A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT01655992 A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) Status TERMINATED Phase PHASE3
NCT01654185 Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT01653366 Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway Status TERMINATED Phase NA
NCT01640665 Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Status COMPLETED Phase PHASE1
NCT01633060 A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Status TERMINATED Phase PHASE3